Pila Pharma AB (“Pila Pharma” or the “Company”) announced on February 17 the outcome of the Company’s series TO2 warrants. A total of 1,798,853 series TO2 warrants were exercised, corresponding to approximately 12% of the total number of outstanding warrants, for subscription of 3,597,706 shares at a subscription price of SEK 1.50 per share. This provides Pila Pharma with approximately SEK 5.4m before transaction costs. The dilution effect amounts to approximately 7.9% for shareholders who did not exercise any warrants. Below are our thoughts on the news:
- Higher subscription rate than expected: TO2 contributed SEK 5.4 million, exceeding our estimates, thereby strengthening the cash position and postponing the short-term capital need, which we view positively from a valuation perspective.
- Enables clinical value drivers: Existing funds are now considered sufficient to finance a clinical study in obesity.
- Additional capital will be required: A broader acceleration of the clinical development program during 2026–2027 is, however, expected to require external capital beyond the TO2 proceeds.
- Continued strong shareholder confidence: The outcome, combined with the previously oversubscribed rights issue and insider participation, indicates solid access to capital markets and confidence in the Company’s development plan.
Analyst Group’s View on the Outcome
We view it positively that Pila Pharma receives SEK 5.4m, which exceeded our expectations somewhat, as in our analysis following the H2 report we assumed an exercise rate of approximately 8%. The capital injection strengthens the Company’s liquidity position and extends its estimated cash runway. Pila Pharma has taken important steps toward clinical development across all indications in recent months and is now expected to accelerate clinical development to realize the potential of its development portfolio.
In our latest equity research report, we assumed an acceleration of clinical development during 2026, with study initiations in both type 2 diabetes and obesity, while a smaller clinical study in erythromelalgia is estimated to commence in 2027. Given the current financial position, this development is assessed to require additional external capital beyond the proceeds from TO2.
However, the capital injection from TO2 is expected to enable the Company to achieve further clinical milestones and thereby unlock additional value drivers by initiating and completing clinical studies in obesity using currently available cash. We expect further clarity regarding the continued clinical development at a capital markets day planned in the coming weeks, at which exposure data from the preclinical obesity study is also expected to be available.
Finally, we assess the outcome as an additional positive indication of Pila Pharma’s ability to attract capital, in line with the oversubscribed rights issue of 293.5% during the summer of 2025. This is particularly noteworthy given the valuation discrepancy between the share price during the subscription period and the subscription price of SEK 1.50 per share, indicating continued strong shareholder confidence. Prior to the end of the subscription period, CEO Gustav H. Gram and Chairperson Dorte X. Gram announced their intention to subscribe for shares, which, according to Analyst Group, reflects confidence in the clinical progress achieved to date and in the forward development plan.
In summary, the outcome of TO2 was somewhat higher than we had estimated, which we view positively from a valuation perspective, as it provides greater scope for Pila Pharma to accelerate clinical development and thereby realize the potential of its development portfolio. Existing funds are now assessed to be sufficient to fully finance an initial clinical obesity study, which may contribute to reducing operational risk ahead of a potential future capital raise. At the same time, exposure data from the preclinical obesity study is expected to constitute a decisive data point regarding the future clinical development plan and its associated risk profile for Pila Pharma going forward. Overall, the outcome, in combination with the previously oversubscribed rights issue, represents a sign of strength regarding the Company’s ability to attract capital and the continued confidence from shareholders.
